IFLR1000

Roche $1.7 billion acquisition of Ignyta

22/12/2017
Public acquisition
Select tab

$ 1.7 billion

Announced

22/12/2017

Overview:

  • Roche has acquired Ignyta for $1.7 billion.
  • The target company is an American cancer drugmaker.
  • The acquirer aims to enlarge its oncology portfolio. 
  • Roche used the financial advice of Citi, while BofA Merrill Lynch and JP Morgan acted as financial advisers for Ignyta.
  • The deal is expected to close within the first half of 2018. 

Katrin Kostadinova - Data analyst 

Jurisdictions:

United States
Switzerland

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:
Fried Frank Harris Shriver & Jacobson

Party: Bank of America Merrill Lynch (Financial adviser)

Lawyer: Philip Richter

Latham & Watkins

Party: Ignyta (Target)

Sidley Austin

Party: Roche (Acquirer)

Lawyer: Sharon Flanagan

Related deals